HUP0303801A2 - Heterociklusos alkoxi-, alkil-tio- és alkil-amino-benzazol-származékok, mint 5-hidroxi-triptamin-6 ligandumok, eljárás az előállításukra és ezeket tartalmazó gyógyszerkészítmények - Google Patents

Heterociklusos alkoxi-, alkil-tio- és alkil-amino-benzazol-származékok, mint 5-hidroxi-triptamin-6 ligandumok, eljárás az előállításukra és ezeket tartalmazó gyógyszerkészítmények

Info

Publication number
HUP0303801A2
HUP0303801A2 HU0303801A HUP0303801A HUP0303801A2 HU P0303801 A2 HUP0303801 A2 HU P0303801A2 HU 0303801 A HU0303801 A HU 0303801A HU P0303801 A HUP0303801 A HU P0303801A HU P0303801 A2 HUP0303801 A2 HU P0303801A2
Authority
HU
Hungary
Prior art keywords
optionally substituted
alkyl
aryl
hydrogen atom
independently
Prior art date
Application number
HU0303801A
Other languages
English (en)
Inventor
Yanfang Li
Ping Zhou
Original Assignee
Wyeth
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wyeth filed Critical Wyeth
Publication of HUP0303801A2 publication Critical patent/HUP0303801A2/hu

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/22Anxiolytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D207/00Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/06Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with radicals, containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

A találmány tárgya (I) általános képletű vegyület - ahol W jelentéseSO2, CO, CONH, CSNH vagy (CH2)x; X jelentése O, SOy vagy NR13; Yjelentése CR14 vagy N; Z jelentése CR15 vagy N, azzal a megkötéssel,hogy ha Y jelentése N, akkor Z szükségszerűen CR15; m és x egymástólfüggetlenül 0 vagy 1 , 2 vagy 3; n és p egymástól függetlenül 1, 2vagy 3; R1 jelentése halogénatom, CN, OR16, CO2R17, CONR18R19,CNR2ONR21R22, SO2NR23R24, SOWR25 vagy 1-6 szénatomos alkil-, 2-6szénatomos alkenil-, 2-6 szénatomos alkinil-, 3-6 szénatomoscikioalkil-, cikloheteroalkil-, fenil- vagy heteroarilcsoport; amelyekadott esetben szubsztituáltak; R2, R3, R5, R6, R7, R8, R9, R10 és R11jelentése egymástól függetlenül hidrogénatom vagy adott esetbenszubsztituált 1-6 szénatomos alkilcsoport; R4 jelentése hidrogénatom,CNR26NR27R28 vagy 1-6 szénatomos alkil-, 2-6 szénatomos alkenil-, 2-6szénatomos alkinil-, 3-6 szénatomos cikloalkil-, cikloheteroalkil-,aril- vagy heteroarilcsoport, melyek, mindegyike adott esetbenszubsztituált; R12 jelentése adott esetben szubsztituált 1-6szénatomos alkil-, aril- vagy heteroarilcsoport; y és w jelentése 0, 1vagy 2; R13 jelentése hidrogénatom vagy 1-6 szénatomos alkil-, 2-6szénatomos alkenil-, 2-6 szénatomos alkinil-, 3-6 szénatomoscikloalkil-, cikloheteroalkil-, aril- vagy heteroarilcsoport, melyekmindegyike adott esetben szubsztituált; R14 és R15 jelentése egymástólfüggetlenül hidrogén- vagy halogénatom vagy 1-6 szénatomos alkil-,aril-, heteroaril- vagy 1-6 szénatomos alkoxicsoport, melyek adottesetben szubsztituáltak; R16 jelentése hidrogénatom, COR29 vagy 1-6szénatomos alkil-, 2-6 szénatomos alkenil-, 2-6 szénatomos alkinil-,aril- vagy heteroarilcsoport, melyek mindegyike adott esetbenszubsztituált; R17 és R29 jelentése egymástól függetlenül hidrogénatomvagy 1-6 szénatomos alkil-, 2-6 szénatomos alkenil-, 2-6 szénatomosalkinil-, 3-6 szénatomos cikloalkil-, cikloheteroalkil-, aril- vagyheteroarilcsoport, melyek mindegyike adott esetben szubsztituált; R18,R19, R20, R21, R22, R26, R27 és R28 jelentése egymástól függetlenülhidrogénatom vagy adott esetben szubsztituált 1-6 szénatomosalkilcsoport; R23 és R24 jelentése egymástól függetlenül hidrogénatomvagy 1-6 szénatomos alkil-, aril- vagy heteroarilcsoport, melyek adottesetben szubsztituáltak; és R25 jelentése adott esetben szubsztituált1-6 szénatomos alkil-, aril- vagy heteroarilcsoport; vagy ezeksztereoizomerjei vagy gyógyászatilag elfogadható sói. A találmánykiterjed az (I) általános képletű vegyületek alkalmazására 5-HT6-receptor által befolyásolt rendellenességek gyógykezelésére. Ó
HU0303801A 2001-04-20 2002-04-19 Heterociklusos alkoxi-, alkil-tio- és alkil-amino-benzazol-származékok, mint 5-hidroxi-triptamin-6 ligandumok, eljárás az előállításukra és ezeket tartalmazó gyógyszerkészítmények HUP0303801A2 (hu)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US28564401P 2001-04-20 2001-04-20
PCT/US2002/012512 WO2002085853A2 (en) 2001-04-20 2002-04-19 Heterocyclylalkoxy-, -alkylthio- and -alkylaminobenzazole derivatives as 5-hydroxytryptamine-6 ligands

Publications (1)

Publication Number Publication Date
HUP0303801A2 true HUP0303801A2 (hu) 2004-03-01

Family

ID=23095117

Family Applications (1)

Application Number Title Priority Date Filing Date
HU0303801A HUP0303801A2 (hu) 2001-04-20 2002-04-19 Heterociklusos alkoxi-, alkil-tio- és alkil-amino-benzazol-származékok, mint 5-hidroxi-triptamin-6 ligandumok, eljárás az előállításukra és ezeket tartalmazó gyógyszerkészítmények

Country Status (17)

Country Link
US (2) US6831094B2 (hu)
EP (1) EP1392682A2 (hu)
JP (1) JP2004526781A (hu)
KR (1) KR20030088507A (hu)
CN (1) CN1293073C (hu)
AR (1) AR034588A1 (hu)
AU (1) AU2002309585B2 (hu)
BR (1) BR0209047A (hu)
CA (1) CA2444036A1 (hu)
EA (1) EA200301143A1 (hu)
HU (1) HUP0303801A2 (hu)
IL (1) IL158448A0 (hu)
MX (1) MXPA03009490A (hu)
NO (1) NO20034647L (hu)
PL (1) PL366639A1 (hu)
WO (1) WO2002085853A2 (hu)
ZA (1) ZA200309009B (hu)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003104193A1 (en) * 2002-06-05 2003-12-18 F. Hoffmann-La Roche Ag 1-sulfonyl-4-aminoalkoxy indole derivatives as 5-ht6-receptor modulators for the treatment of cns-disorders
CA2508315A1 (en) * 2002-12-03 2004-06-17 F. Hoffmann-La Roche Ag Aminoalkoxyindoles as 5-ht6-receptor ligands for the treatment of cns-disorders
KR20050101551A (ko) * 2003-02-14 2005-10-24 와이어쓰 5-하이드록시트립타민-6 리간드로서의헤테로사이클릴-3-설포닐인다졸
SE0302760D0 (sv) * 2003-10-20 2003-10-20 Biovitrum Ab New compounds
AU2006291414A1 (en) * 2005-08-15 2007-03-22 Wyeth Azinyl-3-sulfonylindazole derivatives as 5-hydroxytryptamine-6 ligands
CA2619010C (en) * 2005-08-15 2013-10-01 Wyeth Substituted-3-sulfonylindazole derivatives as 5-hydroxytryptamine-6 ligands
CN101432274A (zh) * 2006-04-05 2009-05-13 惠氏公司 作为5-羟色胺-6配体的磺酰基-3-杂环吲唑衍生物
WO2007120596A1 (en) * 2006-04-12 2007-10-25 Wyeth DIHYDRO[1,4]DIOXINO[2,3-e]INDAZOLE DERIVATIVES AS 5-HYDROXYTRYPTAMINE-6 LIGANDS
EP2029550A2 (en) * 2006-06-01 2009-03-04 Wyeth a Corporation of the State of Delaware 1-sulfonylindazolylamine and -amide derivatives as 5-hydroxytryptamine-6 ligands
WO2009006267A2 (en) * 2007-06-28 2009-01-08 Wyeth N'-(2-halobenzylidene)sulfonylhydrazides as intermediates in the manufacture of arylsulfonylindazoles
MX2012013197A (es) 2010-05-12 2013-04-03 Abbvie Inc Inhibidores de indazol de cinasa.
EA022623B1 (ru) 2010-10-06 2016-02-29 ГЛАКСОСМИТКЛАЙН ЭлЭлСи Производные бензимидазола в качестве ингибиторов pi3-киназ
CN104725295B (zh) 2013-12-20 2019-05-24 广东东阳光药业有限公司 芳杂环类衍生物及其在药物上的应用
CN105541693B (zh) 2014-07-08 2018-10-16 广东东阳光药业有限公司 芳杂环类衍生物及其在药物上的应用
MY200629A (en) 2017-08-01 2024-01-06 Theravance Biopharma R&D Ip Llc Pyrazolo and triazolo bicyclic compounds as jak kinase inhibitors
US10851102B2 (en) 2019-01-23 2020-12-01 Theravance Biopharma R&D Ip, Llc Imidazole and triazole containing bicyclic compounds as JAK inhibitors
US11697648B2 (en) 2019-11-26 2023-07-11 Theravance Biopharma R&D Ip, Llc Fused pyrimidine pyridinone compounds as JAK inhibitors

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5274097A (en) * 1988-04-19 1993-12-28 Bayer Aktiengesellschaft 1,3-disubstituted pyrrolidines
DE3835291A1 (de) 1988-04-19 1989-11-02 Bayer Ag 1,3-disubstituierte pyrrolidine
GB9103862D0 (en) * 1991-02-25 1991-04-10 Glaxo Group Ltd Chemical compounds
TW288010B (hu) * 1992-03-05 1996-10-11 Pfizer
WO1995003298A1 (en) 1993-07-19 1995-02-02 Fujisawa Pharmaceutical Co., Ltd. BENZIMIDAZOLE DERIVATIVES USEFUL AS DOPAMINE RECEPTOR ANTAGONIST, 5-HT RECEPTOR AGONIST OR α1 RECEPTOR ANTAGONIST
US5578716A (en) * 1993-12-01 1996-11-26 Mcgill University DNA methyltransferase antisense oligonucleotides
JPH0940646A (ja) 1995-07-27 1997-02-10 Yamanouchi Pharmaceut Co Ltd ベンゼン縮合環誘導体又はその塩
GB9523462D0 (en) 1995-11-16 1996-01-17 Merck Sharp & Dohme Therapeutic agents
WO1998050346A2 (en) * 1997-04-18 1998-11-12 Smithkline Beecham Plc Acetamide and urea derivatives, process for their preparation and their use in the treatment of cns disorders
WO2001005758A2 (en) 1999-07-15 2001-01-25 Nps Allelix Corp. Indoles and indazoles for the treatment of migraine
PL363241A1 (en) * 2000-12-22 2004-11-15 Wyeth Heterocyclindazole and azaindazole compounds as 5-hydroxytryptamine-6 ligands
TW593278B (en) * 2001-01-23 2004-06-21 Wyeth Corp 1-aryl-or 1-alkylsulfonylbenzazole derivatives as 5-hydroxytryptamine-6 ligands
TW200401641A (en) * 2002-07-18 2004-02-01 Wyeth Corp 1-Heterocyclylalkyl-3-sulfonylindole or-indazole derivatives as 5-hydroxytryptamine-6 ligands
KR20050101551A (ko) * 2003-02-14 2005-10-24 와이어쓰 5-하이드록시트립타민-6 리간드로서의헤테로사이클릴-3-설포닐인다졸

Also Published As

Publication number Publication date
US6831094B2 (en) 2004-12-14
WO2002085853A3 (en) 2002-12-19
US20030078286A1 (en) 2003-04-24
AR034588A1 (es) 2004-03-03
IL158448A0 (en) 2004-05-12
AU2002309585B2 (en) 2008-01-31
EP1392682A2 (en) 2004-03-03
KR20030088507A (ko) 2003-11-19
CN1293073C (zh) 2007-01-03
ZA200309009B (en) 2005-02-21
NO20034647L (no) 2003-11-20
WO2002085853A2 (en) 2002-10-31
MXPA03009490A (es) 2004-02-12
EA200301143A1 (ru) 2004-02-26
NO20034647D0 (no) 2003-10-17
BR0209047A (pt) 2004-08-10
US20050065185A1 (en) 2005-03-24
JP2004526781A (ja) 2004-09-02
CN1518548A (zh) 2004-08-04
CA2444036A1 (en) 2002-10-31
PL366639A1 (en) 2005-02-07

Similar Documents

Publication Publication Date Title
HUP0303801A2 (hu) Heterociklusos alkoxi-, alkil-tio- és alkil-amino-benzazol-származékok, mint 5-hidroxi-triptamin-6 ligandumok, eljárás az előállításukra és ezeket tartalmazó gyógyszerkészítmények
AR063804A1 (es) Compuestos de azoniabiciclo[2.2.2]octano
CA2487542A1 (en) Indole, azaindole and related heterocyclic 4-alkenyl piperidine amides
MXPA03011638A (es) Nuevos derivados de 4-piperazinil indol con afinidad por el receptor 5-ht6.
RS28004A (en) Azabicycle-substituted fused- heteroaryl compounds for the treatment of disease
RU2010116253A (ru) Производные n-гидроксилсульфонамида как новые физиологически применимые доноры нитроксила
HUP0204399A2 (en) Pteridine compounds for the treatment of psoriasis, process for their preparation, pharmaceutical compositions containing them and their use
PE20070218A1 (es) COMPUESTOS DE CICLOALQUILO AMINO-HIDANTOINA Y USO DE ESTOS PARA LA MODULACION DE ß-SECRETASA
HRP20070430T3 (en) (3-oxo-3,4-dihydro-quinoxalin-2-yl-amino)-benzamide derivatives and related compounds as glycogen phosphorylase inhibitors for the treatment of diabetes and obesity
WO2003080580A3 (en) Quinoline derivatives and their use as 5-ht6 ligands
AR034203A1 (es) Derivados de 1-aril- o 1-alquilsulfonilbenzazol como ligandos de 5-hidroxitriptamina-6, un metodo para su preparacion, composicion farmaceutica y el uso de los mismos para la fabricacion de un medicamento
SE0104332D0 (sv) Therapeutic agents
PE20030703A1 (es) Inhibidores de la 17b-hidroxiesteroide deshidrogenasa tipo 3
DE60311821D1 (de) Dibenzylaminverbindung und deren medizinische verwendung
TW200738682A (en) Isoquinoline derivatives
NO20056007L (no) Dobbel NK1/NK3 antagonister for behandling av schizofreni
NO20075169L (no) Nye imidazo (1,5-A)pyndindenvater, fremgangsmate for fremstilling og farmasoytiske sammensetninger som inneholder samme.
NO20090952L (no) N-(aminoheteroaryl) - lh - indol-2-karboksamidderivater og fremstilling og terapeutisk anvendelse derav
CA2445190A1 (en) Indole, azaindole and related heterocyclic amidopiperazine derivatives
MX2009006024A (es) Derivados de heteroaril piridopirimidona sustituidos.
JP2006507326A5 (hu)
HRP20040429B1 (en) Sulphonamide derivatives, the preparation thereof and the application of same as medicaments
NO20025641D0 (no) Substituerte 1-aminoalkyl-laktamer og deres anvendelse som muscarin-reseptor-antagonister
AR037907A1 (es) Derivados de azaindolilalquilamina como ligandos de 5-hidroxitriptamina-6
TW200635896A (en) N-(heteroaryl)-1H-indole-2-carboxamide derivatives, preparation thereof and therapeutic application thereof

Legal Events

Date Code Title Description
FD9A Lapse of provisional protection due to non-payment of fees